Once-weekly GLP-1 receptor agonists, especially semaglutide, produced significantly greater HbA1c reductions and weight loss than DPP-4 inhibitors in a large real-world type 2 diabetes population.
−4.1 kg vs −1.3 kgweight loss with semaglutide vs DPP-4 inhibitors over 12 months
What the researchers found
Semaglutide users achieved 1.7% HbA1c reduction and 4.1 kg weight loss vs 0.9% and 1.3 kg for DPP-4 inhibitor users over 12 months, with GLP-1 patients at least twice as likely to hit composite endpoints.
Why it matters
While clinical trials have established GLP-1 superiority, this real-world evidence confirms those benefits hold up in everyday clinical practice, supporting guideline recommendations to prioritize GLP-1 therapies for patients needing both glycemic control and weight management.
The numbers in context
Compared two treatment cohorts. Primary outcomes: HbA1c and weight changes.
How the study worked
Observational cohort study using linked IQVIA PharMetrics Plus and Ambulatory EMR databases (January 2017–April 2022), with inverse probability of treatment weighting to adjust for baseline differences between groups.
Who was studied
Adults with type 2 diabetes on OW GLP-1 RAs or DPP-4 inhibitors
What this study cannot tell us
Observational design limits causal inference despite statistical adjustments; US-focused data may not generalize globally; relatively small semaglutide subgroup (N=354); limited to 12-month follow-up; potential for residual confounding.
How to read the evidence
Moderate evidence from a large real-world observational study using statistical adjustments, but limited by non-randomized design and potential residual confounding.
When this study was published
Published in 2024 using data through April 2022, providing recent real-world evidence for once-weekly GLP-1 medications.
The bigger picture
This study adds to the growing body of real-world evidence supporting current guidelines that recommend GLP-1 receptor agonists as preferred second-line therapies for type 2 diabetes, especially when weight management is a priority alongside glycemic control.
Questions still open
- Do the real-world advantages of GLP-1 RAs over DPP-4 inhibitors persist beyond 12 months?
- How do newer agents like tirzepatide compare to semaglutide in real-world head-to-head analyses?
- What patient characteristics predict the greatest benefit from switching from DPP-4i to GLP-1 RA therapy?
Common questions
How much better are weekly GLP-1 shots than DPP-4 pills for type 2 diabetes?
Do GLP-1 medications work as well in real life as they do in clinical trials?
Read the original research
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Clinical drug investigation, 44(4), 271-284
Citation
Tan, Xi; Divino, Victoria; Amamoo, James; Xie, Lin; Coyle, Katharine B; Gamble, Cory L; Guevarra, Mico; Paprocki, Yurek; King, Aaron A. (2024). Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).. Clinical drug investigation, 44(4), 271-284. https://doi.org/10.1007/s40261-024-01354-2